- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
LLS Creates Research Partnership With Celgene
The Leukemia & Lymphoma Society (LLS) and the biopharmaceutical Celgene Corporation have announced a partnership that aims to identify and fund promising blood cancer research projects.
The partnership is the first for LLS's new "Targets, Leads & Candidates Program," a novel approach to venture philanthropy partnerships with the pharmaceutical industry.
The LLS regards such partnerships as crucial for patients since they can potentially bring together innovation from academia and the resources of the pharmaceutical industry in order to expedite novel, life-saving therapies.
"LLS is pleased to be collaborating with Celgene, a company known for innovation in research, to advance both basic academic research in the hematological malignancies, as well as the clinical-development stage projects in our TAP pipeline," said LLS Chief Mission Officer Louis J. DeGennaro, Ph.D. "As always, our goal is getting new therapies to patients more quickly."
"Celgene shares with LLS a deep commitment to high impact treatment for patients with leukemia and lymphoma," said Thomas Daniel, M.D., Celgene President, Research and Early Development. "Through this relationship, we look forward to working with LLS to accelerate delivery of promising therapies to patients."